公开(公告)号：DE69912058D1

公开(公告)日：2003-11-20

申请号：DE69912058

申请日：1999-04-28

Applicant: ACADEMIA SINICA TAIPEH T AI PE

Inventor： ROFFLER STEVE ,  CHERN JI-WANG ,  LEU YE-LIN

IPC: C07D491/04 ,  C07H15/26 ,  C07H15/203 ,  C07D491/22 ,  A61K31/70

Abstract: The present invention features proactive antitumor compounds of the following formula: wherein R is COOZ; Z being H, alkali metal, alkaline earth metal, an ammonium group which is optionally substituted with one or more alkyl groups, or a carboxyl protecting group; each of R , R , and R , independently, is OH or OR ; R being a hydroxyl protecting group; X is benzene or pyridine, optionally substituted with R ; R being H, C1-5 alkyl, C1-5 alkoxy, NO2, F, Cl, Br, SO3H, and CN; R is H or OH; and each of n and m, independently, is 0 or 1; or a salt thereof.

公开(公告)号：AU2015287696A1

公开(公告)日：2017-02-16

申请号：AU2015287696

申请日：2015-07-10

Applicant: ACADEMIA SINICA

Inventor： HSIEH PATRICK CH ,  WU PEI-JUNG ,  ROFFLER STEVE ,  CHENG BILL ,  LIANG CHI-MING

IPC: C07K2/00 ,  A61K38/00

Abstract: Disclosed herein is a multiple drugs delivery system and its uses in treating diseases. The multiple drugs delivery system includes, an anti-PEG antibody for directing the PEGylated therapeutic to the treatment site; and a hydrogel for retaining the anti-PEG antibody and/or the PEGylated therapeutic at the treatment site for at least 3 days. The hydrogel is selected from the group consisting of hyaluronan (HA) or a derivative of HA, collagen, gelatin, fibronectin, fibrinogen, alginate, chitosan, and a synthetic biocompatible polymer. The anti-PEG antibody and the hydrogel are present in the mixture in a ratio from about 1:1 (v/v) to 1:100 (v/v). At least two dosages of the PEGylated therapeutic, which may be the same or different, are administered to the subject, with each dosage being given at about 1 hour to about 1 week apart. Accordingly, a novel method of treating a subject having cancer or ischemia disease is also provided.

公开(公告)号：DE69912058T2

公开(公告)日：2004-04-29

申请号：DE69912058

申请日：1999-04-28

Applicant: ACADEMIA SINICA TAIPEH T AI PE

Inventor： ROFFLER STEVE ,  CHERN JI-WANG ,  LEU YE-LIN

IPC: C07D491/04 ,  C07H15/26 ,  C07H15/203 ,  C07D491/22 ,  A61K31/70

Abstract: The present invention features proactive antitumor compounds of the following formula: wherein R is COOZ; Z being H, alkali metal, alkaline earth metal, an ammonium group which is optionally substituted with one or more alkyl groups, or a carboxyl protecting group; each of R , R , and R , independently, is OH or OR ; R being a hydroxyl protecting group; X is benzene or pyridine, optionally substituted with R ; R being H, C1-5 alkyl, C1-5 alkoxy, NO2, F, Cl, Br, SO3H, and CN; R is H or OH; and each of n and m, independently, is 0 or 1; or a salt thereof.

公开(公告)号：AU2015287696B2

公开(公告)日：2018-06-14

申请号：AU2015287696

申请日：2015-07-10

Applicant: ACADEMIA SINICA

Inventor： HSIEH PATRICK CH ,  WU PEI-JUNG ,  ROFFLER STEVE ,  CHENG BILL

IPC: C07K2/00 ,  A61K38/00

Abstract: Disclosed herein is a multiple drugs delivery system and its uses in treating diseases. The multiple drugs delivery system includes, an anti-PEG antibody for directing the PEGylated therapeutic to the treatment site; and a hydrogel for retaining the anti-PEG antibody and/or the PEGylated therapeutic at the treatment site for at least 3 days. The hydrogel is selected from the group consisting of hyaluronan (HA) or a derivative of HA, collagen, gelatin, fibronectin, fibrinogen, alginate, chitosan, and a synthetic biocompatible polymer. The anti-PEG antibody and the hydrogel are present in the mixture in a ratio from about 1:1 (v/v) to 1:100 (v/v). At least two dosages of the PEGylated therapeutic, which may be the same or different, are administered to the subject, with each dosage being given at about 1 hour to about 1 week apart. Accordingly, a novel method of treating a subject having cancer or ischemia disease is also provided.